The FDA has granted orphan drug status to rilzabrutinib, an investigational therapy to prevent pain crises in sickle cell ...

An algorithm is helping to reduce the number of unnecessary hospital admissions for children with sickle cell.

Malaria remains one of the most common triggers of sickle cell crises in patients living in malaria-endemic regions, while sickle cell disease (SCD) also predisposes patients to frequent malaria ...